ADC Therapeutics SA Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
ADC Therapeutics SA quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q2 2024.
  • ADC Therapeutics SA Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$36.5M, a 25.3% increase year-over-year.
  • ADC Therapeutics SA annual Net Income (Loss) Attributable to Parent for 2023 was -$240M, a 52.8% decline from 2022.
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$36.5M +$12.4M +25.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$46.6M +$12.8M +21.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q2 2023 -$48.9M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$59.4M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.